Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay-Reference-Cited by-同舟云学术

Analytical validation of NeXT Personal®, an ultra-sensitive personalized circulating tumor DNA assay

Published:2024-03-14 Issue:1 Volume:15 Page:200-218
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Northcott Josette¹,Bartha Gabor¹,Harris Jason¹,Li Conan¹,Navarro Fabio C.P.¹,Pyke Rachel Marty¹,Hong Manqing¹,Zhang Qi¹,Ma Shuyuan¹,Chen Tina X.¹,Lai Janet¹,Udar Nitin¹,Saldivar Juan-Sebastian¹,Ayash Erin¹,Anderson Joshua¹,Li Jiang¹,Cui Tiange¹,Le Tu¹,Chow Ruthie¹,Velasco Randy Jerel¹,Mallo Chris¹,Santiago Rose¹,Bruce Robert C.¹,Goodman Laurie J.¹,Chen Yi¹,Norton Dan¹,Chen Richard O.¹²,Lyle John M.¹²

Affiliation:

1. Personalis, Inc., Fremont, CA 94555, USA

2. Co-last authors

Publisher

Impact Journals, LLC

Reference47 articles.

1. Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling;Nutzinger;Ann Oncol,2021

2. Liquid biopsies for residual disease and recurrence;Tie;Med,2021

3. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling;Say;Cancer Discov,2017

4. Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors;Martens;Cancers (Basel),2021

5. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence;Boydell;Clin Cancer Res,2019

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer;Trends in Cancer;2024-07